Dual Index Sequencing Market Size, Share, and Industry Analysis, By Type (Product {System, Kits, Consumables, and Others} and, Service), By Technology (Whole Genome Sequencing, RNA Sequencing, Amplicon Sequencing, and Others), By Application (Molecular Biology Research, Drug Discovery, Diagnostics, and Others), By End User (Pharmaceutical and, Biotechnology Companies, Research and Academic Institutes, Diagnostics Centers, and Others), and Regional Forecast, 2026-2034

The global dual index sequencing market is anticipated to grow due to its vital functions in next-generation sequencing workflows, enabling accurate sample multiplexing and minimizing index hopping or cross-contamination. By attaching unique identifiers to both ends of DNA fragments, dual index systems ensure high data reliability, vital in clinical diagnostics. The market’s growth is being driven by the rising demand for precision medicine, the increasing adoption of NGS in diagnostics and translational research, and the need for cost-efficient high-throughput sequencing in large cohort studies. Additionally, falling sequencing costs, government-funded genomics initiatives, and strategic collaborations between sequencing technology providers and diagnostic labs, as well as rising investment ventures, are accelerating adoption. As NGS continues to expand into clinical and population health applications, dual index sequencing is expected to remain an indispensable technology, ensuring accuracy, scalability, and reliability.

• For instance, in July 2024, Element Biosciences, Inc., received over USD 277.0 million in Series D investment to support its growing global customer base with disruptive DNA sequencing and multi-omics technologies, such as rising investment in technological advancements to drive growth.

Dual Index Sequencing Market Driver

Rising Adoption of Sequencing in Clinical Diagnostics to Drive Market Growth

One of the major factors driving the growth of the market is the increasing adoption of sequencing in clinical diagnostics. With the rising prevalence of chronic diseases such as oncology, genetic disorders, and infectious diseases, the demand for precise and accurate testing and clinical diagnostics is increasing. 

Additionally, increasing collaboration among academic and market players is fueling the demand for novel platforms. Advancements in sample preparation and the introduction of cloud-based bioinformatics solutions are reducing barriers to adoption. Finally, the expansion of precision medicine, personalized therapeutics, and agriculture/genome editing research continues to accelerate demand for sequencing technologies across both academic and commercial sectors.

Comparative Study Analyzing Sensitivity of Diagnostic Methods (in %)

In December 2024, an article was published titled ‘Diagnostic Accuracy of Enzyme-Linked Immunosorbent Assay Compared with Polymerase Chain Reaction in Diagnosing Helicobacter pylori in Patients with Gastric Problems’ that reported a 2019 study analyzing diagnostic methods for identifying H. pylori and their sensitivity. It reported that, based on the PCR method, 51.9% of the 102 samples tested positive, compared to 30.4% positivity for IgA using ELISA. The sensitivity and specificity reported were 66.8% and 75.0%, respectively, exhibiting greater specificity of the PCR techniques. 

Dual index sequencing market Restraint

Increased Cost Per Sample to Hamper Adoption and Restrict Market Growth

One of the major restraints for the dual index sequencing market is the increased cost per sample, which can hamper widespread adoption, especially among smaller diagnostic labs and academic research groups with limited budgets. Unique dual index (UDI) adapters are more expensive compared to combinatorial or single index adapters as they require higher synthesis quality, stringent quality control, and a larger pool of unique barcodes to avoid cross-contamination. 

• For example, Oklahoma State University. Reported that sequencing kits were priced as high as USD 2,151.0. Such high prices may adversely affect the market growth. 

Dual index sequencing market Opportunity

Increasing Adoption of Molecular Testing to Offer Lucrative Market Expansion Opportunities for Growth 

The increasing adoption of molecular testing is creating significant market expansion opportunities as it enables more precise detection of complex diseases. The rising incidence of chronic diseases to driving hospitals and diagnostic labs to integrate sequencing and molecular assays into clinical workflows. This shift is further supported by regulatory approvals and reimbursement frameworks, which are improving patient access and driving test volumes. 

Furthermore, the global market is witnessing heightened research and development, strategic collaboration leading to novel product launches in the area to provide valuable tools for biocatalysis applications.

• For instance, in April 2025, Illumina Inc. collaborated with Tempus AI, Inc. to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumina AI technologies with Tempus's comprehensive multimodal data platform to train genomic algorithms and ultimately accelerate clinical adoption of molecular testing for patients. Such technological advancements are expected to open new avenues for growth.

Key Insights

The report covers the following key insights:

• Technological Advancements in Indexing Strategies
• Overview of Genomic Programs, key Countries, 2024
• Overview of Applications of Dual Index Sequencing
• Application Expansion in Large-Scale Genomics Programs
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

Segmentation

Analysis by Type

By type, the market is divided into products (system, kits, consumables, and others) and service.

Systems are expected to dominate the global dual index sequencing market. The high segmental share is attributed to increasing demand for sequencing platforms required for the NGS workflow. High upfront demand for advanced platforms reflects their critical role in delivering high-throughput, accurate, and scalable sequencing. Continuous technological advancements, including improved read lengths, real-time analysis, and automation, further reinforce the importance of these systems. Moreover, growing adoption in diagnostics, oncology, and large-scale population genomics projects accelerates system placements worldwide. Supported by strong government and private investments in genomics infrastructure, the system segment remains the dominant driver of market growth.

• For instance, in February 2024, Integrated DNA Technologies (IDT) partnered with Element Biosciences, Inc. to enable more efficient and streamlined next-generation sequencing (NGS) workflows for users of the AVITI System. High-quality adapters, universal blockers, and library amplification primer mixes designed exclusively for the AVITI System are also launched. These products can support a wide range of applications, and such developments are expected to drive growth in the segment. 

Analysis by Technology

Based on technology, the market is classified into whole genome sequencing, RNA sequencing, amplicon sequencing, and others. 

The whole genome sequencing segment is expected to dominate the global dual index sequencing market. Whole Genome Sequencing (WGS) technology dominates as it provides comprehensive and clinically relevant genetic insights, enabling accurate detection of disease-causing genes. Also, their wide adoption in oncology, rare disease diagnosis, and precision medicine has fueled demand, as these approaches cover both broad and targeted applications. Additionally, many key players are focusing on new product launches of adapters suitable for this technology—such developments are expected to drive the segmental growth. Furthermore, strong government-funded genomics initiatives and pharmaceutical R&D investments continue to prioritize whole genome studies, reinforcing their segment leadership.

• For instance, in October 2023, Twist Bioscience launched Twist Full Length Unique Dual Index Adapters to enable PCR-free whole genome sequencing (WGS) and multiplexing at scale. The new adapters enabled NGS library preparation in a single ligation step and eliminating the need for PCR and amplification. Such developments streamline the workflows and enhance the time efficiency by potentially reducing the risk of errors, such as expanded benefits to drive the growth in the segment.

Analysis by Application

By application, the market is divided into molecular biology research, drug discovery, diagnostics, and others.

The diagnostics segment is expected to hold a substantial market share of the global dual index sequencing market. The dominating market share is due to accurate sample identification and elimination of index hopping are critical in clinical testing. Dual indexing ensures high reliability in multiplexed sequencing, essential for applications such as oncology panels, rare disease detection, and infectious disease surveillance. Moreover, the rising burden of cancer, genetic disorders, and viral outbreaks is pushing healthcare providers to adopt reliable sequencing solutions with unique dual indexes. Supported by government genomics programs and regulatory push for NGS-based diagnostics, the diagnostic segment remains the largest and fastest-growing end-use area for dual index sequencing. 

• For instance, in August 2021, Royal Philips collaborated with New York Langone Health’s Department of Pathology, which leveraged the company’s Genomics Workspace to integrate into their EMR environment. This will enable the largest cancer sequencing test in the industry, helping to guide more confident treatment decisions and care pathways for patients who have received a cancer diagnosis. Dual index sequencing is often used in such NGS sequencing to reduce cost by enabling multiple samples at a time. Such a crucial role of these adapters in clinical diagnostics is expected to drive growth in the segment.

 Analysis by End User 

By end user, the market is divided into pharmaceutical and biotechnology companies, research and academic institutes, diagnostics centers, and others. 

Diagnostic centers are expected to hold a considerable market share over the forecast period. The high market share of these diagnostic centers is attributed to the extensive use of dual index sequencing for diagnostic applications in tools such as whole genome and exome sequencing, amplicon, as well as RNA sequencing. Also, technological advancement for new product launches, along with their approvals, facilitates the adoption of these adapters by diagnostic centers.

Furthermore, established players are engaging in strategic collaborations and partnerships to expand their product offerings in the segment.

• For instance, in August 2024, Illumina, Inc. received approval from the U.S. FDA for its in vitro diagnostic (IVD) TruSight Oncology (TSO) Comprehensive test and its first two companion diagnostic (CDx) indications—such developments are expected to drive the growth of the segment.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. 

Request for Customization   to gain extensive market insights.

North America accounted for the largest global dual index sequencing market share in 2024. The market growth is driven by a combination of technological, clinical, and policy factors, resulting in higher adoption. The rising prevalence of cancer and genetic disorders has created a strong demand for comprehensive genomic profiling, causing hospitals and diagnostic labs to adopt NGS for precision medicine and targeted therapy selection. Furthermore, strong collaborations between academic centers, pharmaceutical companies, and sequencing technology providers are driving translational research and biomarker discovery, fueling the clinical and commercial growth of the NGS market in the region.

• For instance, in April 2024, the American Society of Cancer Society released Global Cancer Statistics, 2024, on global cancer facts and trends. According to the findings, an estimated 20 million cancer cases were newly diagnosed in 2022, and 9.7 million people died from the disease worldwide. Such a high prevalence of cancer augments the demand for diagnostics, thus driving the market growth. 

Europe is expected to hold a substantial global enzyme and inhibitor market share. Large-scale national genomics programs drive the region's high market growth. Also, government support results in integration of NGS into routine diagnostics, particularly for oncology, rare diseases. Moreover, partnerships between pharmaceutical companies and European hospitals are fueling biomarker discovery and companion diagnostics development, directly increasing demand for high-throughput sequencing platforms and consumables.

• For instance, in September 2024, Takara Bio Europe, a subsidiary of Takara Bio Inc., launched the Shasta Single-Cell System at the 2024 Human Cell Atlas General Meeting. This high-throughput NGS solution enables novel biomarker discovery in oncology research. These NGS solutions increasingly use dual index sequencing adapters. These factors drive the growth in the region.

Asia Pacific is expected to grow with a significant CAGR during the forecast period. The regional growth is attributed to the increasing burden of chronic diseases and cancer is creating demand for early genetic testing, pushing hospitals and diagnostic labs to integrate NGS-based workflows. Additionally, falling sequencing costs and local manufacturing of reagents/instruments in China and India are making advanced sequencing more accessible, accelerating adoption in healthcare systems. Many key companies are focusing on strategic collaboration and partnership to commercialize the growing market.

• For instance, in June 2025, Novogene launched Novogene Korea Limited, a wholly owned subsidiary headquartered in Seoul. This strategic expansion deepened the company’s long-standing engagement with Korea's biomedical and biotech sectors, reinforcing its commitment to delivering rapid, high-quality, and cost-effective multi-omics services tailored to local research needs—such developments are expected to drive growth and innovation in the dual index sequencing market in the Asia Pacific.

Key Players Covered

The global dual index sequencing market is consolidated with the presence of a few groups and a large number of emerging companies.

The report includes the profiles of the following key players:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• New England Biolabs. (U.S.)
• Paragon Genomics, Inc. (U.S.)
• BD. (U.S.)
• ABclonal, Inc. (China)
• Takara Bio Inc. (Japan)
• Twist Bioscience Corporation (U.S.)

Key Industry Developments

• In April 2025, Twist Bioscience Corporation launched the Twist High Throughput (HT) Unique Dual Index (UDI) Adapter System to enable multiplexing and sample batching at scale. This development broadens the company’s product portfolio of indexing solutions, which includes HT UDI adapters as well as full-length adapters that enable key applications such as population genomics and PCR-free whole genome sequencing. 
• In April 2024, Oxford Nanopore Technologies collaborated with BugSeq to provide fully automated analysis solutions for rapid pathogen identification and antimicrobial resistance.